Meeting
2014 ASCO Annual Meeting
A phase I study to assess the safety, tolerability, and PK of dovitinib (D) in combination with gemcitabine (G) and capecitabine (C) in patients with advanced solid tumors.
Authors
Gerald J. Fetterly
Roswell Park Cancer Institute, Buffalo, NY
Gerald J. Fetterly , Laura Pitzonka , Yujie Zhao , Grace K. Dy , Renuka V. Iyer , Susan Taubes , Jose Ricardo Perez , Kenneth W. Culver , John Wilton , Krystin Mongiardo , Wei Tan , William E. Brady , Amy Whitworth , Alex A. Adjei , Wen Wee Ma
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
Pharmacology
Clinical Trial Registration Number
NCT01497392
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 2603)
DOI
10.1200/jco.2014.32.15_suppl.2603
Abstract #
2603
Poster Bd #
66
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 1 results of CYT-0851, a monocarboxylate transporter (MCT) inhibitor, in combination with capecitabine (cape) or gemcitabine (gem) in advanced solid tumors.
First Author: Ryan C. Lynch
Poster
2023 ASCO Annual Meeting
A phase I trial of sequential dosing of sonidegib and pembrolizumab in advanced solid tumors (aST) and non–small-cell lung cancer (NSCLC).
First Author: Mohamed Shanshal
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
First Author: Wang Yk
Poster
2022 ASCO Annual Meeting
A phase I trial of elimusertib in combination with cisplatin or with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma.
First Author: Ryan Leibrandt